$40.65
5.83% yesterday
Nasdaq, Jun 06, 10:05 pm CET
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Tonix Pharmaceuticals Holding Corp. Stock price

$40.65
+21.77 115.31% 1M
+22.30 121.53% 6M
+7.67 23.26% YTD
-307.51 88.32% 1Y
-465,239.35 99.99% 5Y
-5,215,999,959.35 100.00% 10Y
-1,279,959.35 100.00% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+2.24 5.83%
ISIN
US8902604094
Symbol
TNXP
Sector
Industry

Key metrics

Market capitalization $297.75m
Enterprise Value $166.03m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.54
P/S ratio (TTM) P/S ratio 29.66
P/B ratio (TTM) P/B ratio 1.55
Revenue growth (TTM) Revenue growth -2.05%
Revenue (TTM) Revenue $10.04m
EBIT (operating result TTM) EBIT $-72.45m
Free Cash Flow (TTM) Free Cash Flow $-59.95m
Cash position $131.72m
EPS (TTM) EPS $-22.25
P/E forward negative
P/S forward 24.49
EV/Sales forward 13.65
Short interest 12.40%
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

Buy
100%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
10 10
2% 2%
100%
- Direct Costs 7.05 7.05
10% 10%
70%
2.99 2.99
22% 22%
30%
- Selling and Administrative Expenses 41 41
12% 12%
407%
- Research and Development Expense 35 35
53% 53%
344%
-70 -70
31% 31%
-695%
- Depreciation and Amortization 2.70 2.70
41% 41%
27%
EBIT (Operating Income) EBIT -72 -72
32% 32%
-722%
Net Profit -132 -132
34% 34%
-1,314%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Neutral
GlobeNewsWire
2 days ago
CHATHAM, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, being held June 11-14, 2025, in Barcelona, Spain.
Neutral
GlobeNewsWire
16 days ago
CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals participated in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase.
Neutral
GlobeNewsWire
17 days ago
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD)
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 81
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today